Gefzest 250mg Tablet 30's

About

Gefzest 250mg Tablet contains Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that selectively targets the intracellular phosphorylation of the EGFR, which is involved in the growth and proliferation of cancer cells. It is particularly effective in patients with non-small cell lung cancer (NSCLC) who have activating mutations in the EGFR gene. By blocking this signaling pathway, gefitinib inhibits tumor cell growth, induces apoptosis, and reduces angiogenesis, leading to significant clinical responses and improved progression-free survival in selected patient populations. This targeted therapy offers a crucial alternative to conventional chemotherapy, especially for patients with specific genetic profiles, improving their prognosis and quality of life.

Uses

• Non-small cell lung cancer (NSCLC) with EGFR mutations.
• Advanced or metastatic NSCLC.
• First-line treatment for EGFR-mutated NSCLC.
• Patients who have failed prior chemotherapy.

Directions For Use

Take orally once daily, with or without food. Swallow the tablet whole.

Benefits

• Targeted therapy for EGFR-mutated NSCLC.
• Improves progression-free survival.
• Oral administration for convenience.
• Reduces tumor size and symptoms.
• Offers a non-chemotherapeutic option.
• Generally well-tolerated compared to traditional chemotherapy.

Side Effects

• Diarrhea
• Rash (acne-like)
• Nausea
• Vomiting
• Anorexia
• Stomatitis
• Dry skin
• Pruritus
• Liver enzyme elevation
• Interstitial lung disease (rare but serious)
• Ocular disorders (e.g., conjunctivitis)
• Asthenia

Safety Measures

• Alcohol - No specific interaction, but excessive alcohol can exacerbate gastrointestinal side effects and liver strain.
• Pregnancy - Contraindicated; can cause fetal harm. Effective contraception is required.
• Breastfeeding - Not recommended; discontinue breastfeeding during treatment due to potential harm to the infant.
• Liver - Use with caution in patients with hepatic impairment; monitor liver function closely. Dose adjustment may be needed.
• Kidney - Use with caution in patients with severe renal impairment; no specific dose adjustment typically needed for mild-moderate.
• Lung - Can cause severe interstitial lung disease (ILD), which can be fatal. Monitor for new or worsening respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.